Pierre Fabre Pharmaceuticals has entered a research project in translational medicine on a drug target in oncology with David L. Rimm, MD, Ph.D., Professor of Pathology at Yale School of Medicine and the Pierre Fabre’s R&D Translational Medicine department headed by Dr. Alexandre Passioukov.   The collaboration focuses on a precision medicine approach to develop a first-in-class antibody-drug conjugate (ADC) identified by the Pierre Fabre R&D team. Both partners will work on the transl...